Mind Medicine (MindMed) Inc. (MNMD)

NASDAQ: MNMD · Real-Time Price · USD
12.43
-0.21 (-1.66%)
At close: Oct 22, 2025, 4:00 PM EDT
12.45
+0.02 (0.16%)
Pre-market: Oct 23, 2025, 8:50 AM EDT
-1.66%
Market Cap945.77M
Revenue (ttm)n/a
Net Income (ttm)-114.52M
Shares Out 76.09M
EPS (ttm)-1.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,241,302
Open12.52
Previous Close12.64
Day's Range11.88 - 12.63
52-Week Range4.70 - 14.30
Beta3.31
AnalystsStrong Buy
Price Target26.71 (+114.88%)
Earnings DateOct 31, 2025

About MNMD

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 74
Stock Exchange NASDAQ
Ticker Symbol MNMD
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for MNMD stock is "Strong Buy." The 12-month stock price target is $26.71, which is an increase of 114.88% from the latest price.

Price Target
$26.71
(114.88% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

MindMed Announces New Employee Inducement Grant

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...

8 days ago - Business Wire

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Mind Medicine (MNMD) is advancing its lead drug MM120 through Phase 3 trials for anxiety and depression, positioning for long-term upside. MNMD's strong cash reserves, disciplined spending, and extend...

8 days ago - Seeking Alpha

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Needham initiated coverage on Mind Medicine Inc. (NASDAQ:MNMD), or MindMed, on Monday. The late-stage clinical biopharmaceutical company is developing novel product candidates to treat brain health di...

9 days ago - Benzinga

MindMed Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...

4 weeks ago - Business Wire

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

NEW YORK--(BUSINESS WIRE)--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidat...

4 weeks ago - Business Wire

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain...

6 weeks ago - Business Wire

MindMed to Participate in September Investor Conferences

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...

2 months ago - Business Wire

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Brandi L. Roberts - Chief Financial Officer Daniel Rollings Karlin - Chief Me...

2 months ago - Seeking Alpha

MindMed Reports Q2 2025 Financial Results and Business Updates

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain...

2 months ago - Business Wire

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...

3 months ago - Business Wire

MindMed to Participate in June Investor Conferences

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to tr...

5 months ago - Business Wire

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to t...

5 months ago - Business Wire

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...

5 months ago - Business Wire

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - Chief Executive ...

5 months ago - Seeking Alpha

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to t...

6 months ago - Business Wire

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain...

6 months ago - Business Wire

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain...

6 months ago - Business Wire

MindMed Appoints Matt Wiley as Chief Commercial Officer

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain...

7 months ago - Business Wire

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ET Company Participants Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - CEO Dan Karlin...

8 months ago - Seeking Alpha

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain...

8 months ago - Business Wire

MindMed to Present at Leerink's Global Healthcare Conference 2025

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain ...

8 months ago - Business Wire

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain...

8 months ago - Business Wire

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage biopharmaceutical company developing novel product candidates to treat brain health di...

9 months ago - Business Wire

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain...

9 months ago - Business Wire

MindMed to Be Added to the Nasdaq Biotechnology Index

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain heal...

11 months ago - Business Wire